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ABSTRACT
Objectives: The purpose of this study was to compare short-term outcomes in children born
between 24 and 34 weeks’ gestation, according to observed antenatal corticosteroids (ACS)-to-
birth intervals. Research question: ‘Is there a difference in short-term outcomes between
observed ACS-to-birth intervals across a range of gestational ages at birth?’
Methods: Cohort study assessing differences in incidence of short-term neonatal outcomes
according to the observed interval between the last administration of ACS and birth. Linear,
non-weighted GEE models with an independence working correlation structure were fitted to
infant level data providing valid point estimates for either incidence or rate differences (binary
outcomes) or average differences (continuous outcomes).
Results: Of 886 children, 35.9% were born within 2 days after the last administration of ACS,
32.2% within 2 to 7 days, 14.1% within 8 to 14 days, and 17.8% more than 14 days after. Across
gestational ages at birth, there were no differences in birth weight between children born at an
ACS-to-birth interval of 7 days or less compared tomore than 7 days, nor were there differences
in respiratory outcomes, cerebral outcomes, or composite outcome.
Conclusion: Drawing conclusions on the importance of the ACS-to-birth interval is difficult due
to the post-hoc nature of the variable. In the absence of tools to better estimate if and when
PTB will occur, it might not have any value in daily practice, regardless of whether there is an
optimal ACS-to-birth interval or not.
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Introduction
Preterm birth (PTB), defined as delivery prior to
37 weeks’ gestation, remains a challenging problem
within the field of perinatal medicine. It is the lead-
ing cause of neonatal morbidity and mortality
worldwide [1]. Without appropriate antenatal and
neonatal treatment, prematurely born babies who
survive are at increased risk of lifelong disability and
poor quality of life, which brings about high health-
care costs [2]. The most prevalent complication of
prematurity is respiratory distress syndrome (RDS). It
affects up to 50% of neonates born before
28 weeks’ gestation and a third of those born
before 32 weeks [1].
Infant mortality and morbidity following preterm
birth can be reduced by interventions provided to
the mother before or during labor, and to the pre-
term infant after birth. In 1972, Liggins and Howie
published the first randomised controlled trial on
maternal administration of corticosteroids in
humans, showing a significant decrease in RDS inci-
dence [3]. According to the most recent evidence,
administration of antenatal corticosteroids (ACS)
reduces RDS incidence, on average, with 34% (RR
0.66, 95%CI[0.56–0.77]). Perinatal death is, on aver-
age, reduced with 28% (RR 0.72, 95%[CI 0.58, 0.89]),
with mainly a reduction in neonatal death (RR 0.69,
95%CI[0.59, 0.81]). Additional beneficial effects of
ACS are a reduction in intraventricular hemorrhage
(IVH)(RR 0.55, 95%CI[0.40, 0.76]) and necrotising
enterocolitis (NEC)(RR 0.50, 95%CI[0.32, 0.78]).
Results on neurodevelopment are inconclusive [1].
Liggins and Howie suggested that the beneficial
effects of a complete course of corticosteroids on
RDS are greatest if delivery takes place more than
24 hours and less than 7 days after the first injec-
tion of ACS [3]. This suggested interval of optimal
effect on RDS was supported by subgroup analysis
in the Cochrane review on ACS of 2006 [4]. An
individual patient meta-analysis on the timing of
ACS was suggested in the updated review [1].
Obstetrical management is greatly influenced by
this 7-day interval, which is reflected in, for
instance, administration of (weekly) repeat doses
of ACS or the bulk of literature on the prediction
of PTB within 7 days after presentation (cervical
length, biomarkers, prediction models, . . .) [5–9].
The goal of this study was to compare short-term
outcomes in children born between 24 and 34 weeks’
gestation in the Maternal Intensive Care unit of Ghent
University Hospital, Belgium, according to observed
ACS-to-birth intervals.
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Methods
Study design and population
The observational data originates from the preterm birth
register of Ghent University Hospital, a referral center for
high-risk obstetric patients in Belgium. The register was
created in 2016 and includes all women who delivered
from 24 + 0 to 33 + 6 weeks’ gestation. Patients with the
diagnosis of intrauterine fetal death at admission or
expecting a fetus with a major congenital disorder that
could influence neonatal outcomes were not included
since the main goal of the registry is to explore neonatal
and long-term outcomes according to obstetrical man-
agement. Maternal data was obtained retrospectively
from 2012 till 9 July, 2017. From 10 July, 2017, data was
collected prospectively, after obtaining informed consent
of the parents to be. Neonatal data was extracted from
the already operational neonatal database and imported
into the register. Patient involvement was limited to con-
senting in the registration of the data and using the data
for scientific purposes. Based on the current literature,
a set of important variables was collected and managed
using REDCap (Research Electronic Data Capture),
a secure, web-based application designed to support
data capture for research studies [10]. Of the core out-
come set for evaluation of interventions to prevent pre-
term birth, all but one core neonatal outcomes were
included in the register (not included is harm from inter-
vention). Only one of the four core maternal outcome
was included (PPROM) [11]. No other core outcome sets
on PTB are available.
Research question
Is there a difference in short-term outcomes between
observed ACS-to-birth intervals across a range of
gestational ages at birth?
Data analysis
In our center, when patients are admitted for threaten-
ing PTB, a two injection course of ACS (1:1 mixture of
betamethasone-acetate and betamethasone-
phosphate) is initiated or completed. As regards repeat-
ing ACS, the policy (since 2014) is to
● Repeat ACS when more than 7 days elapsed and
a new episode of threatened PTB occurs, 2 injec-
tions of 12 mg betamethasone with an interval 24
of hours are given (full repeat course)
● Repeat ACS weekly when there is threatened PTB
at a gestational age of less than 28 weeks, weekly
injections of 12 mg betamethasone, with
a maximum of 3 repeated gifts, are given (weekly
partial repeat course)
Before 2014, only one course of ACS was given (no-
repeat ACS/repeat ACS weekly). Treatment can differ in
patients referred from other hospitals.
We considered the interval between the last
administration of ACS and birth, further referred to
as the ACS-to-birth interval. In 8% of mothers, dates
of last administration of ACS were missing. These
mothers and neonates were excluded from the ana-
lysis. As for the hour of the last administration of
ACS, there were 27.8% missing data (225 cases).
Since exclusion would have resulted in
a considerably smaller dataset, we decided to
restrict the analyses to discrete (interval per day,
starting from the first injection of the last course)
and categorical (interval after first injection of the
last course of <24 h, 24–47 h, 2–7 d, 8–14 d, and
>14 d; and interval of <7 d and >7 d) ACS-to-birth
intervals.
Short-term outcomes were anthropometry, mortality
in the neonatal intensive care unit (NICU), RDS, surfac-
tant use, days of mechanical ventilation, days of contin-
uous positive airway pressure (CPAP), chronic lung
disease (CLD), NEC, mild intracranial morbidity (IVH
grade 1–2, periventricular leukomalacia (PVL) grade 1),
severe intracranial morbidity (IVH grade 3–4, PVL grade
2–4), and a composite neonatal outcome of NICU-
mortality, CLD, NEC, retinopathy of prematurity (ROP),
and severe intracranial morbidity, with andwithout RDS.
Definitions of variables and outcomes are available
in Online Resource 1.
All outcome variables were binary, except for
anthropometry measures and number of days of ven-
tilation and CPAP, which were continuous variables.
We assessed differences in incidence of the binary
neonatal outcomes and differences in metrics for
anthropometry between the categorical ACS-to-birth
intervals. Gestational age at administration of the last
ACS course and gestational age at birth were cate-
gorised in gestational age of <26 weeks, 27 or
28 weeks, 29 till 31 weeks, and 32 weeks or more.
To adequately handle clustering due to multiple
births, we adopted a Generalised Estimating Equations
(GEE) approach [12,13]. Non-weighted GEE models with
an independence working correlation structure were
fitted to infant level data. In the possible presence of
informative cluster size (i.e. outcomes and between-
group differences in the outcome being associated with
cluster size), the choice of an independent working cor-
relation structure has been advocated to warrant an
infant level interpretation of the results [14]. Linear GEEs
were fitted since these provide valid point and interval
estimates for either incidence or rate differences (binary/
multinomial outcomes) or average differences (continu-
ous outcomes).
Statistical analysis and visualization was done with
R version 3.4.3 using packages ‘geepack’ and ‘ggplot2ʹ.
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Results
Between 2012 and 2018, 813 mothers delivered at
a gestational age of 24 + 0 to 33 + 6 weeks in Ghent
University Hospital. The maternal demographics and
obstetrical characteristics of our database are available
in Online Resource 2. After exclusion of missing data
on the last course of ACS, 753 mothers and 904 neo-
nates were used for analysis.
All mothers included in the database received ACS.
Betamethasone was given in 96.7% of cases, 2.9%
received dexamethasone, and in 0.4% the type of ACS
was missing. When betamethasone was given, the time
interval between the two injections of the initial course,
most often was 24 hours (58.8%). In 8.8%, the second
injection was given after 12 hours, and in 11.4% the
interval was missing. Twenty per cent had an incom-
plete course (due to imminent birth)(19.9%). Of all
patients who had an indication for a repeat course,
24.1% received a full repeat course, and 29.2% received
weekly partial repeat courses (which is, respectively,
8.9% and 7.8% of the study population).
The last dose of ACS given was also the first and
only course in 83.3% of patients.
For further analysis, when born between 24 and
26 weeks, only children of whom the parents chose
for active management (i.e. the couple took an
informed decision to want active obstetrical (fetal
monitoring, caesarean section when indicated) and
neonatal intensive care) were included. Children of
whom the parents did not choose active management
passed away at the delivery ward in the proximity of
the parents. This resulted in an exclusion of 18 children
and brought the new total to 886 neonates.
ACS-to-birth interval
Of 886 children, 35.9% were born within 2 days after
the last administration of ACS, 32.2% within 2 to
7 days, 14.1% within 8 to 14 days, and 17.8% more
than 14 days after. When ACS were given to the
mother at a gestational age of 26 weeks or less,
35.5% of neonates were born within 2 days, 34.3% at
2 to 7 days, 7% at 8 to 14 days, and 23.3% at more than
14 days after the last administration of ACS. When
given at a gestational age of 27 to 28 weeks, these
percentages were, respectively, 21.4%, 23.2%, 18.8%,
and 36.6%; at a gestational age of 29 to 31 weeks,
35.4%, 36.4%, 18.1%, and 10.2%; and at a gestational
age of 32 weeks or more, 61.8%, 33.1%, 5.1%, and 0.0%,
respectively. The distribution of the gestational age at
which the last course of ACS was given, per ACS-to-
birth interval category, is visualized in Figure 1. The
distribution in days is visualized in Figure 2. When we
consider the first administration of ACS, 29.9% of chil-
dren were born within 2 days after administration of
the first course, 27.3% within 2 to 7 days, 15.0% within
8 to 14 days and 27.8% more than 14 days later.
Short-term outcomes according to ACS-to-birth
interval (Table 1)
Overall mortality in the cohort was low. Less than 1%
(7/886, 0.8%) of neonates was stillborn. All but one
stillborn children were born within 7 days after the
last ACS administration. There were 32 deaths during
admission at NICU (3.6%). The majority (81.3%) was
born within 7 days after the last ACS administration.
Half of the children who died were born at or below
Figure 1. Distribution of the gestational age at last antenatal corticosteroid (ACS) administration according to the observed ACS-to
-birth interval (categorical).
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26 weeks gestational age. Only two deaths occurred at
a gestational age of 29 weeks or more, both within the
2 to 7 days ACS-to-birth interval.
The mean birth weight at the intervals was:
1435 ± 458 g at interval ≤2 d, 1349 ± 485 g at interval
2–7 d, 1438 ± 402 g at interval 8–14 d, and
1664 ± 411 g at interval >14 d. For head circumference
the mean values were: 27.4 ± 3.3 cm at ≤2 d,
27.1 ± 2.9 cm at 2–7 d, 27.7 ± 2.5 cm at 8–14 d, and
29.2 ± 2.3 cm at >14 d; and for length, respectively:
39.5 ± 4.3 cm, 38.9 ± 4.7 cm, 39.9 ± 3.9 cm, and
41.8 ± 3.4 cm.
Of children born within 2 days after the last
administration of ACS, 72.5% were diagnosed with
RDS. For the intervals 2 to 7 days, 8 to 14 days, and
>14 days, the percentages were, respectively, 64.5%,
53.7%, and 51.6%. Per extra interval day, there was
a decrease of incidence in RDS of 0.7 ± 0.2% (95%
confidence interval (CI)[0.4, 1.1]). The use of surfac-
tant decreased with increasing ACS-to-birth interval
(per day – 0.5 ± 0.2%, 95%CI[−0.8, −0.2]). For the
intervals ≤2 days, 2 to 7 days, 8 to 14 days, and
>14 days, the percentages of surfactant use were,
respectively, 51.9%, 41.0%, 30.4%, and 35.3%. The
risk of need for ventilation decreased with increasing
interval (per day −0.5 ± 0.2% (95%CI[−0.8, −0.2%]).
For the intervals 2 to 7 days, 8 to 14 days, and
>14 days, the percentages were, respectively, 52.8%,
41.8%, 33.6%, and 38.0%. Almost all ventilated chil-
dren with RDS received surfactant (97.1%). The dis-
tribution of CPAP use in the four intervals was as
follows: ≤2 d: 64.2%, 2–7 d: 56.5%, 8–14 d: 60.8%,
and >14 d: 47.5%, with a decrease in incidence per
ACS-to-birth interval day of 0.5 ± 0.2% [95%CI: −0.8,
−0.2]. Chronic lung disease was most prevalent in the
less than 2-day interval: ≤2 d: 19.5%. Percentages in
the other intervals were: 2–7 d: 17.4%, 8–14 d: 13.3%,
and >14 d: 8.4%. The incidence of CLD decreased per
extra ACS-to-birth interval day: −0.4 ± 0.1% (95%CI
[−0.6, −0.2]).
There were relatively more cases of mild intracranial
morbidity (IVH grade 1–2, PVL grade 1–3) in the ≤2 d
(17.9%) and 2–7 d interval (21.1%) compared to the
8–14 d (12.0%) and >14 d interval (2.5%). The majority
Figure 2. Distribution of the gestational age at last antenatal corticosteroid (ACS) administration according to the observed ACS-to
-birth interval (continuous, in days).
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(93.6%) of extreme preterm born children were born
within these intervals (representing 22% of all children
born within these 2 intervals). Per extra ACS-to-birth
interval day, there was a decrease in mild intracranial
morbidity of 0.6 ± 0.1% (95%CI[−0.7, −0.4%]). There
were few cases of severe intracranial morbidity (IVH
grade 3–4, PVL grade 4–5): ≤2 d: 2.5%, 2–7 d: 2.1%,
8–14 d: 1.6%, and >14 d: 2.5%.
There were only 19 cases of NEC (2.2%): ≤2 d: 2.8%,
2–7 d: 2.1%, 8–14 d: 2.4%, and >14 d: 0.6%.
For the composite adverse neonatal outcome (NICU
mortality, RDS, CLD, severe intracranial morbidity, NEC,
or ROP), there was a 0.4 ± 0.2% (95%CI[−0.7, −0.1%])
decrease in composite outcome for every extra ACS-to-
birth interval day. When born at or within 2 days after
the last administration of ACS, 80.4% of children had at
least one of the complications included in the compo-
site adverse neonatal outcome. At 2–7% the propor-
tion was 75.4%, at 8–14 d 67.0%, and at >14 d 68.5%.
When RDS was excluded from the composite
adverse neonatal outcome, the decrease in composite
outcome was 0.5 ± 0.1% (95%CI[−0.7, −0.2%]) per
extra day. For the intervals 2 to 7 days, 8 to 14 days,
and >14 days, respectively, 25.3%, 25.5%, 18.6%, and
13.1% of neonates had at least one of the morbidities
included in the composite adverse neonatal outcome.
The distribution of short-term outcomes per ACS-to-
birth interval is summarized in Table 1.
Neonatal outcomes according to ACS-to-birth
interval across gestational ages at birth (Table 2)
Almost all children born at 26 weeks’ gestation or less
were born within 7 days after the last ACS administra-
tion (100 (96.2%) vs 4 (3.8%)), which precludes
comparison between an interval between ACS admin-
istration and birth of 7 days or less and an interval of
more than 7 days.
For the remaining gestational age groups, there were
no differences in birth weight between the two inter-
vals, nor were there differences in respiratory outcomes
(RDS, days of ventilation, days of CPAP, CLD), in cerebral
outcomes (mild/severe IVH/PVL), or in composite out-
come (RDS in- and excluded). Figures 3 and 4 are heat-
maps depicting, respectively, RDS and the composite
outcome (RDS excluded) in the function of gestational
age at ACS administration and gestational age at birth.
Discussion
Main findings
Considering the last given course of ACS, more than
one third (35.9%) of neonates were born within
24 hours after the first injection of the course.
Another third (32.2%) was born between 2 and
7 days after the last administration of ACS. For a gesta-
tional age of 27 weeks or more, no differences were
found in respiratory, cerebral, and composite out-
comes between children born at 7 days or less after
maternal ACS administration and children born at
>7 days after the last ACS administration. Per extra
ACS-to-birth interval day (and thus gestational age),
there was a slight decrease in neonatal morbidity.
Strengths and limitations
For the first time in Belgium, a multidisciplinary data-
base on PTB was created, integrating obstetrical infor-
mation, neonatal management and outcomes. The
database contains a wealth of information on the
core neonatal outcomes for PTB. REDCap enabled
quality control of data input. Patients were included
over seven consecutive years. This article is an attempt
to link obstetrical with neonatal data.
For statistical inferences, we respected the non-
independence of outcomes in multiples, often
neglected in perinatal epidemiologic research. We did
not, however, account for non-independence of out-
comes in neonates from mothers that had been
admitted for more than one pregnancy during the
study period. Since only 2.5% of women were included
more than once, we have reason to believe that this
additional level of clustering may have had a negligible
impact as compared to clustering due to multiple preg-
nancies (which accounted for 22.3% of included preg-
nancies). This was confirmed by a sensitivity analysis.
No causal inferences were made, this study only
reports estimates and associations within a tertiary
population experiencing preterm birth. Since analyses
had a descriptive aim, we did not perform extensive
multivariate regressions.
Table 1. Short-term outcomes according to last ACS-to-birth
interval.
Last ACS-to-birth interval
Outcome ≤ 2 d 2–7 d 8–14 d >14 d Total
RDS
n, (%) 17 missing
224
(72.5)
182
(64.5)
66
(53.7)
80
(51.6)
552
(63.5)
Surfactant
n, (%) 12 missing
161
(51.9)
116
(41.0)
38
(30.4)
55
(35.3)
370
(42.3)
Ventilation
n, (%)
168
(52.8)
119
(41.8)
42
(33.6)
60
(38.0)
389
(43.9)
CPAP
n, (%)
204
(64.2)
161
(56.5)
76
(60.8)
75
(47.5)
516
(58.7)
CLD
n, (%) 167 missing
53
(19.5)
40
(17.4)
13
(13.3)
10
(8.4)
116
(16.1)
NEC
n, (%)
9
(2.8)
6
(2.1)
3
(2.4)
1
(0.6)
19
(2.1)
Mild intracranial
n, (%)
57
(17.9)
60
(21.1)
15
(12.0)
4
(2.5)
136
(15.3)
Severe intracranial
n, (%)
8
(2.5)
6
(2.1)
2
(1.6)
4
(2.5)
20
(2.3)
NICU mortality
n, (%)
14
(4.5)
12
(4.2)
3
(2.4)
3
(1.9)
32
(3.6)
Composite
n, (%) 126 missing
232
(80.4)
185
(75.4)
69
(67.0)
86
(68.5)
572
(75.3)
Composite, RDS excl n, (%) 139
missing
71
(25.3)
61
(25.5)
19
(18.6)
16
(13.1)
167
(22.4)
Total 318 285 125 158 886
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This is a monocentric study in a hospital with
approximately 1000 deliveries a year. A comparison
and aggregation with data from other maternal inten-
sive care units in Belgium would have been favourable.
Multicenter prospective collection of data did start in
mid-2018, but retrospective collection of data was not
deemed feasible.
Finally, we used a broad definition of RDS (any need
for respiratory support at birth) and were not able to
compare the four ACS-to-birth intervals with no
administration of ACS because all patients received at
least one injection of ACS.
Interpretation
The presumed superiority of an ACS-to-birth interval of
2 to 7 days has significantly influenced obstetrical
management: tests for prediction of birth within
Table 2. Differences in neonatal outcomes between birth ≤7 days and birth >7 days after ACS administration, across gestational
ages at birth.
Gestational age at birth
Outcome 24–26 weeks* 27–28 weeks 29–31 weeks 32–34 weeks
ACS ≤ 7 days: n = 603 (68.1%) 100 (96.2%) 93 (80.2%) 240 (65.2%) 170 (57.0%)
ACS > 7 days: n = 283 (31.9%) 4 (3.8%) 23 (19.8%) 128 (34.8%) 128 (43.0%)
Birthweight (g ± SE)
[95%CI]
238 ± 75
[10, 466]
0 ± 61
[−187, 187]
7 ± 37
[−105, 118]
57 ± 46
[−83, 197]
RDS (% ± SE)
[95%CI]
−4.4 ± 2.2
[−11.0, 2.1]
16.3 ± 9.4
[−12.2, 44.8]
5.5 ± 5.3
[−10.7, 21.6]
−8.4
[−20.5, 3.7]
Surfactant use (% ± SE)
[95%CI]
−9.7 ± 3.1
[−19.0, −0.4]
14.4 ± 10.4
[−17.3, 46.0]
−4.0
[−20.8, 12.9]
0.3
[−14.2, 14.7]
Ventilation (% ± SE)
[95%CI]
−15.0 ± 3.7
[−26.3, −3.7]
7.8 ± 10.1
[−22.8, 38.5]
−4.8 ± 5.5
[−21.4, 11.7]
0.3 ± 4.8
[−14.2, 14.7]
CPAP (% ± SE)
[95%CI]
−9.5 ± 8.4
[−35.1, 16.1]
3.1 ± 2.0
[−2.9, 9.2]
−0.9 ± 1.0
[−4.1, 2.2]
0.2 ± 0.5
[−1.4, 1.7]
CLD (% ± SE)
[95%CI]
−42.9 ± 5.8
[−60.3, −25.4]
−0.9 ± 12.4
[−38.5, 36.7]
−4.0 ± 3.5
[−14.5, 6.5]
−0.3 ± 1.5
[−4.8,-4.1]
Mild IVH/PVL (% ± SE)
[95%CI]
42.0 ± 5.4
[25.8, 58.2]
9.4 ± 11.1
[−24.2, 43.1]
6.0 ± 3.8
[−5.6, 17.7]
3.7 ± 2.0
[−2.4, 9.8]
Severe IVH/PVL (% ± SE)
[95%CI]
−17.0 ± 23.5
[−88.4, 54.4]
1.1 ± 1.1
[−2.2, 4.3]
−0.7 ± 1.6
[−5.4, 4.1]
−1.0 ± 1.3
[−4.8, 2.8]
NEC (% ± SE)
[95%CI]
6.0 ± 2.4
[−1.1, 13.1]
2.1 ± 5.0
[−12.9, 17.1]
−0.3 ± 1.3
[−4.3, 3.7]
−0.7 ± 0.8
[−3.1, 1.6]
Composite, with RDS (% ± SE)
[95%CI]
−3.3 ± 1.8
[−8.8, 2.3]
8.3 ± 7.7
[−15.2, 31.7]
4.0 ± 5.3
[−12.1, 20.1]
−0.8 ± 7.0
[−22.0, 20.5]
Composite, without RDS (% ± SE)
[95%CI]
−27.7 ± 4.9
[−42.5, −12.8]
0.2 ± 12.7
[−38.2, 38.7]
−5.1 ± 4.1
[−17.7, 7.4]
−2.9 ± 2.6
[−10.7, 4.8]
*Shaded due to the low number of patients delivering at an ACS-to-birth interval >7 days.
Figure 3. Heatmap on RDS in the function of gestational age at last antenatal corticosteroid (ACS) administration (weeks) and
gestational age at birth (weeks).
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7 days are commercially available [15–17], prediction
models and applications have been developed (7), and
management is directed towards the probability of
delivery between 2 and 7 days [5,18]. This practice is
mainly based on the first RCT on ACS, in which the
occurrence of RDS in liveborn children was lowest
when the study entry-delivery interval was between 2
and 7 days [3]. However, these results are post-hoc
analyses on post-hoc defined interventions (in this
case, an interval). Therefore, these results need to be
interpreted with caution [19]. Randomly assigning
patients to ACS-to-birth intervals, however, is not pos-
sible without reliance on a highly accurate prediction
model of the date of delivery. Therefore, only associa-
tions can be looked after and causal inference is not
possible [20]. Nevertheless, the ACS-to-birth interval is
commonly reported as having an influence on or redu-
cing certain neonatal adverse outcomes.
Conclusion
Drawing conclusions on the importance of the ACS-to-
birth interval is difficult due to the post-hoc nature of
the variable. And, in the absence of tools to better
estimate if and when PTB will occur, it might not
have any value in daily practice, regardless of whether
there is an optimal ACS-to-birth interval or not.
We believe that, taking into account the major
advances in neonatal care, the most important measure
is to prevent PTB and, when PTB is deemed inevitable,
to administer ACS. When given at a time of high
suspicion of preterm birth, the interval between admin-
istration of ACS and birth might be of less importance.
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